Covered recipient · General Payments record
GREGORY W MATTINGLEY
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$601,325.30
722 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $316,895.27 | 119 |
| Travel and Lodging | $116,356.11 | 256 |
| Consulting Fee | $89,411.16 | 29 |
| Honoraria | $64,537.78 | 7 |
| Food and Beverage | $14,117.86 | 310 |
| Education | $7.12 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 7 of 15; records 301–350 of 722 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GREGORY W MATTINGLEY
NPI 1215933379 · CMS profile ID 236102
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
SAINT CHARLES, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 7 of 15; records 301–350 of 722 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215933379?year=2019&recipient=provider&page=7#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GREGORY W MATTINGLEY, NPI 1215933379, CMS profile ID 236102. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 15; records 301–350 of 722 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215933379?year=2019&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). GREGORY W MATTINGLEY, NPI 1215933379, CMS profile ID 236102. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 15; records 301–350 of 722 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215933379?year=2019&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- GREGORY W MATTINGLEY, NPI 1215933379, CMS profile ID 236102, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 15; records 301–350 of 722 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215933379?year=2019&recipient=provider&page=7#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
722 matching records · $601,325.30 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 301–350 of 722.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Alkermes, Inc. | $21,020.00 | 08/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686608717 | CMS |
| Allergan Inc. | $3.97 | 08/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670784011 | CMS |
| Ironshore Pharmaceuticals Inc. | $5.00 | 08/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707563855 | CMS |
| Ironshore Pharmaceuticals Inc. | $223.98 | 08/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707563857 | CMS |
| Ironshore Pharmaceuticals Inc. | $5.00 | 08/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707563859 | CMS |
| Ironshore Pharmaceuticals Inc. | $223.99 | 08/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707563861 | CMS |
| Ironshore Pharmaceuticals Inc. | $5.00 | 08/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707563863 | CMS |
| Ironshore Pharmaceuticals Inc. | $223.99 | 08/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707563865 | CMS |
| Rhodes Pharmaceuticals L.P. | $17.15 | 08/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706745419 | CMS |
| Rhodes Pharmaceuticals L.P. | $8.54 | 07/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706745417 | CMS |
| Janssen Pharmaceuticals, Inc | $860.37 | 07/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658995393 | CMS |
| Janssen Pharmaceuticals, Inc | $60.00 | 07/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658995395 | CMS |
| Sunovion Pharmaceuticals Inc. | $4.11 | 07/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688152143 | CMS |
| Allergan Inc. | $2,500.00 | 07/29/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670784001 | CMS |
| Allergan Inc. | $17.40 | 07/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670784003 | CMS |
| Allergan Inc. | $12.72 | 07/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670784007 | CMS |
| Neos Therapeutics, LP | $14.30 | 07/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705610925 | CMS |
| Neos Therapeutics, LP | $13.97 | 07/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705610133 | CMS |
| Allergan Inc. | $4,375.00 | 07/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783963 | CMS |
| Allergan Inc. | $30.60 | 07/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783967 | CMS |
| Allergan Inc. | $6.12 | 07/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783969 | CMS |
| Allergan Inc. | $118.74 | 07/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783973 | CMS |
| Allergan Inc. | $19.74 | 07/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783979 | CMS |
| Allergan Inc. | $2,500.00 | 07/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783985 | CMS |
| Allergan Inc. | $25.00 | 07/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783987 | CMS |
| Allergan Inc. | $377.29 | 07/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783989 | CMS |
| Allergan Inc. | $21.42 | 07/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783995 | CMS |
| Allergan Inc. | $4,375.00 | 07/23/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783945 | CMS |
| Allergan Inc. | $25.00 | 07/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783947 | CMS |
| Allergan Inc. | $819.39 | 07/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783951 | CMS |
| Allergan Inc. | $104.07 | 07/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783955 | CMS |
| Allergan Inc. | $31.00 | 07/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783959 | CMS |
| Allergan Inc. | $387.96 | 07/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783905 | CMS |
| Allergan Inc. | $4,375.00 | 07/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783907 | CMS |
| Allergan Inc. | $25.80 | 07/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783913 | CMS |
| Allergan Inc. | $34.20 | 07/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783916 | CMS |
| Allergan Inc. | $492.40 | 07/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783920 | CMS |
| Allergan Inc. | $6.00 | 07/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783923 | CMS |
| Allergan Inc. | $125.00 | 07/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783929 | CMS |
| Allergan Inc. | $10.61 | 07/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783931 | CMS |
| Allergan Inc. | $52.33 | 07/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783937 | CMS |
| Allergan Inc. | $36.64 | 07/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783939 | CMS |
| Allergan Inc. | $657.96 | 07/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783859 | CMS |
| Allergan Inc. | $384.61 | 07/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783865 | CMS |
| Allergan Inc. | $2,500.00 | 07/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783869 | CMS |
| Allergan Inc. | $13.62 | 07/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783873 | CMS |
| Allergan Inc. | $4,375.00 | 07/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783875 | CMS |
| Allergan Inc. | $43.00 | 07/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783881 | CMS |
| Allergan Inc. | $332.35 | 07/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783885 | CMS |
| Allergan Inc. | $125.00 | 07/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670783889 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $385,511.93 | 71 |
| PY2024 | Principal investigator | $1,002,661.79 | 106 |
| PY2023 | Principal investigator | $569,554.84 | 100 |
| PY2022 | Principal investigator | $243,940.43 | 72 |
| PY2021 | Principal investigator | $384,699.58 | 89 |
| PY2020 | Principal investigator | $602,612.63 | 82 |
| PY2019 | Principal investigator | $303,620.29 | 105 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
71 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $3,445.60 | 12/31/2025 | Non-covered Recipient Entity SAINT CHARLES PSYCHIATRIC ASSOCIATES AND MIDWEST RESEARCH GROUP | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies | No dispute reported | 06/30/2026 | 1202534249 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $400.00 | 12/11/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916366 |
| Principal investigator 1 | Alkermes, Inc. | $3,300.00 | 12/03/2025 | Non-covered Recipient Entity ST. CHARLES PSYCHIATRIC ASSOCIATES | A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) | No dispute reported | 06/30/2026 | 1208613986 |
| Principal investigator 1 | ABBVIE INC. | $237.64 | 11/25/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202525366 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,950.00 | 11/17/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695421 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $400.00 | 11/14/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916364 |
| Principal investigator 1 | Corium, LLC | $3,500.00 | 11/13/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1181950042 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $3,214.83 | 11/07/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | No dispute reported | 06/30/2026 | 1232946880 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 10/20/2025 | Non-covered Recipient Entity St Charles Psychc Associates | A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) | No dispute reported | 06/30/2026 | 1175237482 |
| Principal investigator 1 | ABBVIE INC. | $3,299.73 | 10/09/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202516381 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695417 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695419 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 09/12/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202510846 |
| Principal investigator 1 | ABBVIE INC. | $5,939.00 | 09/10/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202510446 |
| Principal investigator 1 | ABBVIE INC. | $3,299.73 | 09/04/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202509086 |
| Principal investigator 1 | Corium, LLC | $3,375.66 | 09/03/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1181949996 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $600.00 | 08/22/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695415 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $12,000.00 | 08/21/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | No dispute reported | 06/30/2026 | 1232946139 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $7,500.00 | 08/15/2025 | Non-covered Recipient Entity MIDWEST RESEARCH GROUPST CHARLES PSYCHIATRIC ASSOC | EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA | No dispute reported | 06/30/2026 | 1232946127 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $234.20 | 08/15/2025 | Non-covered Recipient Entity MIDWEST RESEARCH GROUPST CHARLES PSYCHIATRIC ASSOC | EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA | No dispute reported | 06/30/2026 | 1232946131 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,850.00 | 08/14/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES | ITI-007-421 | No dispute reported | 06/30/2026 | 1242356910 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $5,209.05 | 08/13/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916362 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $19,500.00 | 08/08/2025 | Non-covered Recipient Entity MIDWEST RESEARCH GROUPST CHARLES PSYCHIATRIC ASSOC | EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA | No dispute reported | 06/30/2026 | 1232946103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 08/04/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695413 |
| Principal investigator 1 | Corium, LLC | $1,473.96 | 07/29/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1181949994 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $800.00 | 07/23/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916360 |
| Principal investigator 1 | Corium, LLC | $3,346.17 | 07/10/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1181949992 |
| Principal investigator 1 | Janssen Research & Development, LLC | $223.00 | 07/02/2025 | Non-covered Recipient Entity St Charles Psychc Associates | A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) | No dispute reported | 06/30/2026 | 1175237496 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 06/25/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695405 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 06/25/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695407 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 06/25/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 06/25/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695411 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $2,573.50 | 06/13/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916358 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,739.63 | 05/28/2025 | Non-covered Recipient Entity Saint Charles Psychiatric Associates And Midwest Research Group | An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia | No dispute reported | 06/30/2026 | 1235994113 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $600.00 | 05/27/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695403 |
| Principal investigator 1 | Collegium Pharmaceutical, Inc. | $14.58 | 05/22/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and Pharmacokinetic Study of Evening Dosed Methylphenidate Hydrochloride Extended?Release Capsules (HLD200) in Children Aged 4 to 5 Years with Attention Deficit Hyperactivity Disorder. | No dispute reported | 06/30/2026 | 1208627818 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $190.00 | 05/16/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916354 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $5,006.06 | 05/16/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916356 |
| Principal investigator 1 | Corium, LLC | $9,102.69 | 04/24/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1181949950 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,778.00 | 04/23/2025 | Non-covered Recipient Entity St Charles Psychc Associates | A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) | No dispute reported | 06/30/2026 | 1175237489 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $5,364.96 | 04/16/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916350 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $140.00 | 04/16/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916352 |
| Principal investigator 1 | Collegium Pharmaceutical, Inc. | $47.42 | 04/10/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and Pharmacokinetic Study of Evening Dosed Methylphenidate Hydrochloride Extended?Release Capsules (HLD200) in Children Aged 4 to 5 Years with Attention Deficit Hyperactivity Disorder. | No dispute reported | 06/30/2026 | 1208627796 |
| Principal investigator 1 | ABBVIE INC. | $15,000.00 | 04/03/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202472186 |
| Principal investigator 1 | Alkermes, Inc. | $1,850.00 | 04/02/2025 | Non-covered Recipient Entity ST. CHARLES PSYCHIATRIC ASSOCIATES | A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) | No dispute reported | 06/30/2026 | 1208613239 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,330.00 | 04/02/2025 | Non-covered Recipient Entity St Charles Psychc Associates | A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) | No dispute reported | 06/30/2026 | 1175237454 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $6,044.71 | 03/24/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916348 |
| Principal investigator 1 | Corium, LLC | $101,870.22 | 03/19/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1181949880 |
| Principal investigator 1 | Collegium Pharmaceutical, Inc. | $12,900.00 | 03/06/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and Pharmacokinetic Study of Evening Dosed Methylphenidate Hydrochloride Extended?Release Capsules (HLD200) in Children Aged 4 to 5 Years with Attention Deficit Hyperactivity Disorder. | No dispute reported | 06/30/2026 | 1208627894 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,436.00 | 02/24/2025 | Non-covered Recipient Entity St Charles Psychc Associates | A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) | No dispute reported | 06/30/2026 | 1175237472 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $500.00 | 02/21/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695399 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,500.00 | 02/21/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695401 |
| Principal investigator 1 | Alkermes, Inc. | $10,542.00 | 02/20/2025 | Non-covered Recipient Entity ST. CHARLES PSYCHIATRIC ASSOCIATES | A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) | No dispute reported | 06/30/2026 | 1208612795 |
| Principal investigator 1 | Corium, LLC | $3,199.01 | 02/20/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1181949878 |
| Principal investigator 1 | Corium, LLC | $18,411.42 | 02/20/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | An Efficacy and Safety Study w/ Azstarys in Children With ADHD | No dispute reported | 06/30/2026 | 1181949928 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $4,216.85 | 02/18/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916346 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 02/14/2025 | Non-covered Recipient Entity St Charles Psychc Associates | A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. | No dispute reported | 06/30/2026 | 1175237444 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $600.00 | 02/12/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 1242332926 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,500.00 | 02/06/2025 | Non-covered Recipient Entity St Charles Psychiatric Associates | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220816382 |
| Principal investigator 1 | Corium, LLC | $7,030.87 | 02/05/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1181949876 |
| Principal investigator 1 | Corium, LLC | $2,876.95 | 01/29/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1181949874 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,125.00 | 01/29/2025 | Non-covered Recipient Entity ST CHARLES PSYCHIATRIC ASSOCIATES INC | AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 1242329869 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,489.00 | 01/24/2025 | Non-covered Recipient Entity St Charles Psychc Associates | A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) | No dispute reported | 06/30/2026 | 1175237462 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $30.00 | 01/14/2025 | Non-covered Recipient Entity Midwest Research Group | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916344 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $264.55 | 01/10/2025 | Non-covered Recipient Entity Midwest Research Group | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220695423 |
| Principal investigator 1 | Alkermes, Inc. | $17,156.90 | 01/01/2025 | Non-covered Recipient Entity ST. CHARLES PSYCHIATRIC ASSOCIATES | A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) | No dispute reported | 06/30/2026 | 1208627003 |
| Principal investigator 1 | Alkermes, Inc. | $19,633.04 | 01/01/2025 | Non-covered Recipient Entity ST. CHARLES PSYCHIATRIC ASSOCIATES | Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder | No dispute reported | 06/30/2026 | 1208627035 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 01/01/2025 | Non-covered Recipient Entity Midwest Research Group | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220695391 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 01/01/2025 | Non-covered Recipient Entity Midwest Research Group | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220695393 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 01/01/2025 | Non-covered Recipient Entity Midwest Research Group | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220695395 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 01/01/2025 | Non-covered Recipient Entity Midwest Research Group | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220695397 |